VYNE Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 14. Principal Accountant Fees and Services
Baker Tilly US, LLP served as our principal independent registered public accounting firm for the years ended December 31, 2024 and 2023. The following table provides information regarding fees paid by us to Baker Tilly US, LLP for the years ended December 31, 2024 and 2023:
| Year ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| (U.S. dollars in thousands) | ||
| Audit fees(1) | $359 | $379 |
| Tax fees(2) | 4 | 16 |
| Total Fees | $363 | $395 |
(1) Includes professional services rendered in connection with the audit of our annual financial statements, the review of our interim financial statements and fees for registration statements, comfort letters and statutory audits.
(2) Includes professional services rendered for tax compliance services.
Our audit committee’s specific responsibilities in carrying out its oversight of the quality and integrity of our accounting, auditing and reporting practices include the approval of audit and non-audit services to be provided by the external auditor. The audit committee pre-approves all non-audit services provided to us by our independent registered public accounting firm.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.